Key facts
- It has raised $1.3M across 1 recorded rounds; the latest was Accelerator/Incubator in Jan 2020.
- Notable investors include Springboard Enterprises, Brandon Biocatalyst, Eastend Ventures, Southern Angels.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Alyra Biotech
Funding rounds
1 roundsAbout Alyra Biotech
Operator of a bio-pharmaceutical company intended to treat neuroimmune conditions, the immune system, and chronic pain conditions in women. The company offers products for conditions such as chronic pelvic pain, irritable bowel syndrome, painful bladder syndrome, migraine, and endometriosis, enabling women to manage pain and improve overall well-being with targeted, long-term treatments that reduce systemic side effects.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Adelaide, Australia
- Founded
- 2017
- Employees
- 5
- Website
- alyrabiotech.com/
- Ownership
- Privately Held (backing)
Alyra Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Alyra Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Alyra Biotech in its N-PORT filings yet. We sweep new filings monthly.